OncoMatch/Clinical Trials/NCT06812871
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Is NCT06812871 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies furmonertinib for non-small cell lung cancer metastatic.
Treatment: furmonertinib — the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
confirmed EGFR exon 19 deletion mutation(19del)
Required: EGFR L858R
EGFR exon 21L858R mutation (L858R)
Required: EGFR T790M
EGFR exon 20 T790M mutation (T790M)
Excluded: EGFR C797X
Known EGFR exon 20 C797X mutation (C797X)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (third-generation EGFR-TKI) — advanced NSCLC with meningeal metastases
had meningeal metastases after treatment with one third-generation EGFR-TKI
Lab requirements
Blood counts
Absolute neutrophil count <1.5 × 10^9/L; continuous count <100×10^9/L; hemoglobin <90 g/L; Albumin <30 g/L
Kidney function
Serum creatinine >1.5x ULN, and Creatinine clearance <50 mL/min (Measured or calculated by Cockcroft and Gault formula)
Liver function
Alanine aminotransferase > 2.5x ULN; Aspartate aminotransferase >2.5x ULN; Total bilirubin >1.5x ULN; or liver transplant patients with AST and/or ALT > 5x ULN
Cardiac function
Clinically significant resting ECG abnormalities; LVEF <50%; recent history of myocardial infarction, severe or unstable angina, or coronary artery bypass grafting within the past month or heart failure ≥ NYHA 2 class
Lack of adequate bone marrow reserve or organ function...see details in criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify